# US 2019/0314493 A1 · Human cytomegalovirus vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314493 A1
- Document ID: US20190314493A1
- Status: Published application
- Kind: A1
- Application number: 16/389,545
- Filed: 2019-04-19
- Published: 2019-10-17
- Earliest claimed: 2016-10-21
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Giuseppe Ciaramella; Shinu John
- Web page: https://patentgrep.com/patent/US20190314493A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61P 31/22: for herpes viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16171: Demonstrated in vivo effect
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

## Claims

### Claim 1

A human cytomegalovirus (hCMV) vaccine comprising:
i) at least one RNA polynucleotide having one or more open reading frames encoding hCMV antigenic polypeptides gH, gL, UL128, UL130, and/or UL131A, or antigenic fragments or epitopes thereof;
ii) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide gB, or an antigenic fragment or epitope thereof;
iii) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide pp65, or an antigenic fragment or epitope thereof, and
iv) a pharmaceutically acceptable carrier or excipient.

### Claim at position 2

-180. (canceled)

### Claim 181 (depends on 1)

The hCMV vaccine of claim 1, wherein the RNA polynucleotides of (i)-(iii) are formulated in at least one lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid, in an effective amount to induce an immune response in a subject administered at least one dose of the vaccine.

### Claim 182 (depends on 1)

The hCMV vaccine of claim 1, wherein the RNA polynucleotide of (i)-(iii) further encode a 5′ terminal cap, 7mG(5′)ppp(5′)NlmpNp.

### Claim 183 (depends on 1)

The hCMV vaccine of claim 1, wherein at least 80% of the uracil in the open reading frame of (i)-(iii) have a chemical modification selected from 1-methyl-pseudouridine or 1-ethyl-pseudouridine.

### Claim 184 (depends on 183)

The hCMV vaccine of claim 183, wherein the chemical modification is in the carbon-5 position of the uracil.

### Claim 185 (depends on 1)

The hCMV vaccine of claim 1, wherein the efficacy of the vaccine in vaccinated subjects is at least 60%, relative to unvaccinated subjects, following a single dose of the vaccine.

### Claim 186 (depends on 185)

The hCMV vaccine of claim 185, wherein the efficacy of the vaccine in vaccinated subjects is at least 70%, relative to unvaccinated subjects, following a single dose of the vaccine.

### Claim 187 (depends on 186)

The hCMV vaccine of claim 186, wherein the efficacy of the vaccine in vaccinated subjects is at least 80%, relative to unvaccinated subjects, following a single dose of the vaccine.

### Claim 188 (depends on 187)

The hCMV vaccine of claim 187, wherein the efficacy of the vaccine in vaccinated subjects is at least 90%, relative to unvaccinated subjects, following a single dose of the vaccine.

### Claim 189 (depends on 181)

The hCMV vaccine of claim 181, wherein the effective amount is sufficient to produce detectable levels of hCMV gH, gL, UL128, UL130, UL131A, gB and/or pp65 polypeptide as measured in serum of a subject vaccinated with a dose of the vaccine at 1-72 hours post administration.

### Claim 190 (depends on 181)

The hCMV vaccine of claim 181, wherein the effective amount is sufficient to produce a 1,000-10,000 neutralization titer produced by neutralizing antibody against the hCMV gH, gL, UL128, UL130, UL131A, gB and/or pp65 polypeptide as measured in serum of a subject vaccinated with a dose of the vaccine at 1-72 hours post administration.

### Claim 191 (depends on 1)

The hCMV vaccine of claim 1, wherein an anti-hCMV gH, gL, UL128, UL130, UL131A, gB and/or pp65 polypeptide antibody titer produced in a subject vaccinated with a dose of the vaccine is increased by at least 1 log relative to a control, wherein the control is an anti-hCMV gH, gL, UL128, UL130, UL131A, gB and/or pp65 polypeptide antibody titer produced in a subject who has not been administered a vaccine against hCMV.

### Claim 192 (depends on 1)

The hCMV vaccine of claim 1, wherein the anti-hCMV gH, gL, UL128, UL130, UL131A, gB and/or pp65 polypeptide antibody titer produced in a subject vaccinated with a dose of the vaccine is increased at least 2 times relative to a control, wherein the control is an anti-hCMV gH, gL, UL128, UL130, UL131A, gB and/or pp65 polypeptide antibody titer produced in a subject who has not been administered a vaccine against hCMV.

### Claim 193 (depends on 181)

The hCMV vaccine of claim 181, wherein the effective amount is a total dose of 25 μg-200 μg.

### Claim 194 (depends on 193)

The hCMV vaccine of claim 193, wherein the effective amount is a total dose of 25 μg-200 μg.

### Claim 195 (depends on 181)

The hCMV vaccine of claim 181, wherein the ionizable cationic lipid comprises the following compound:

### Claim 196 (depends on 1)

The hCMV vaccine of claim 1, wherein the hCMV vaccine comprises: (a) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide gH; (b) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide gL; (c) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide UL128; (d) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide UL130; (e) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide UL131A; (f) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide gB; and (g) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide pp65.

### Claim 197 (depends on 196)

The hCMV vaccine of claim 196, wherein the RNA polynucleotide of (a) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 189, the RNA polynucleotide of (b) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 190, the RNA polynucleotide of (c) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 191, the RNA polynucleotide of (d) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 172, the RNA polynucleotide of (e) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 193, the RNA polynucleotide of (f) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 162, and or the RNA polynucleotide of (g) comprises a sequence that has at least 90% identity to a RNA polynucleotide sequence encoded by SEQ ID NO: 92.

### Claim 198

A human cytomegalovirus (hCMV) vaccine comprising: (a) at least one RNA polynucleotide comprising nucleotides 46-2437 of SEQ ID NO: 189, (b) at least one RNA polynucleotide comprising nucleotides 46-1045 of SEQ ID NO: 190, (c) at least one RNA polynucleotide comprising nucleotides 46-724 of SEQ ID NO: 191, (d) at least one RNA polynucleotide comprising an nucleotides 46-853 of SEQ ID NO: 172, (e) at least one RNA polynucleotide comprising nucleotides 46-598 of SEQ ID NO: 193, (f) at least one RNA polynucleotide comprising nucleotides 46-2932 of SEQ ID NO: 162, and (g) at least one RNA polynucleotide encoded by SEQ ID NO: 92,
wherein each of the RNA polynucleotides of (a)-(g) are mRNA polynucleotides,
wherein each of the RNA polynucleotides of (a)-(f) further comprises a polyA tail, and wherein the polynucleotide of (g) further comprises a 5′UTR encoded by SEQ ID NO: 146, a 3′UTR encoded by SEQ ID NO: 147, and a polyA tail.

### Claim 199 (depends on 198)

The hCMV vaccine of claim 198, wherein the polyA tail is 100 nucleotides in length.

### Claim 200

A human cytomegalovirus (hCMV) vaccine comprising: (a) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO: 58, (b) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO: 62, (c) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO: 60, (d) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO: 15, (e) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO: 66, (f) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO: 86, and (g) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO: 92,
wherein each of the RNA polynucleotides of (a)-(g) are mRNA polynucleotides,
wherein each of the RNA polynucleotides of (a)-(f) comprises a polyA tail, and wherein the polynucleotide of (g) comprises a polyA tail and further comprises a 5′UTR encoded by SEQ ID NO: 146 and a 3′UTR encoded by SEQ ID NO: 147.

### Claim 201 (depends on 200)

The hCMV vaccine of claim 200, wherein the polyA tail is 100 nucleotides in length.

### Claim 202 (depends on 196)

The hCMV vaccine of claim 196, wherein the hCMV gH polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 59, the hCMV gL polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 61, the hCMV UL128 polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 63, the hCMV UL130 polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 65, the hCMV UL131A polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 67, the hCMV gB protein comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 69; and/or the pp65 protein comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 82.

### Claim 203 (depends on 202)

The hCMV vaccine of claim 202, wherein the hCMV gH polypeptide comprises the amino acid sequence of SEQ ID NO: 59, the hCMV gL polypeptide comprises the amino acid sequence of SEQ ID NO: 61, the hCMV UL128 polypeptide comprises the amino acid sequence of SEQ ID NO: 63, the hCMV UL130 polypeptide comprises the amino acid sequence of SEQ ID NO: 65, the hCMV UL131A polypeptide comprises the amino acid sequence of SEQ ID NO: 67, the hCMV gB protein comprises the amino acid sequence of SEQ ID NO: 69; and the pp65 protein comprises the amino acid sequence of SEQ ID NO: 82.

### Claim 204 (depends on 1)

The hCMV vaccine of claim 1, wherein the RNA polynucleotides are not self-replicating RNA.
